Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)

Phase 1 Completed 52 enrolled University of Alberta Alberta Diabetes Institute · collab Canadian Institutes of Health Research (CIHR) · collab Heart and Stroke Foundation of Canada · collab Women and Children's Health Research Institute, Canada · collab

RandomizedParallel-groupOpen-labelHealth-services research

Summary

The primary objective in this proposed study is to determine the effect of dietary fish oil supplementation compared to standard care metformin treatment, and fish oil in combination with metformin on plasma lipids and apoB-remnant lipoprotein metabolism in overweight-obese young women with PCOS.

Timeline

Start: 2016-06-30
Primary completion: 2020-11-12
Completion: 2020-11-12

Publications

Results Vine DF, Wang Y, Jetha MM, Ball GD, Proctor SD. Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017 Mar 1;102(3):970-982. doi: 10.1210/jc.2016-2854.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fish oil	Other / unclassified	1200 mg	Oral
Subject	Metformin	Small molecule	500 mg	—

Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)

Summary

Timeline

Publications

Drugs

Indications